Cochrane · systematic review · CD010709
Pre‐emptive correction for haemodialysis arteriovenous access stenosis
Ravani, P, Quinn, RR, Oliver, MJ, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 2 · 50%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Scheduled surveillance versus clinical monitoring alone for preventing arteriovenous (AV) access failure
Population: people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Risk of access thrombosis Scheduled surveillance vs clinical monitoring alone | RR 0.95 [0.8, 1.12] | 8 studies · 697 participants | Moderate |
Rate of angiograms Scheduled surveillance vs clinical monitoring alone | RR 1.78 [1.18, 2.67] | 5 studies · 539 participants | Low |
Scheduled surveillance versus clinical monitoring alone for the prevention of arteriovenous (AV) access failure
Population: people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Risk of access loss Scheduled surveillance vs clinical monitoring alone | RR 0.9 [0.71, 1.15] | 6 studies · 662 participants | Moderate |
Mortality Scheduled surveillance vs clinical monitoring alone | RR 1.38 [0.9, 2.11] | 5 studies · 586 participants | Low |